Adalimumab, a monoclonal antibody drug, has become a cornerstone in the treatment of various autoimmune diseases. As a biologic, it targets and neutralizes a specific protein (tumor necrosis factor-alpha, TNF-α) that plays a crucial role in inflammation. The rising emphasis on developing targeted therapies and the increasing prevalence of autoimmune conditions are expected to drive the...